Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

about

A Festschrift in Honor of Edward M. Messing, MD, FACS

P2860

Q58691149-9EAA93B2-F395-4580-AA1B-5FDA6BD70292

P2860

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

Item

http://www.wikidata.org/entity/Q43875491

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@en

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@nl

type

Item

label

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@en

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@nl

prefLabel

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@en

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@nl

P1476

Oncological Outcomes of Sequen ...... uscle Invasive Bladder Cancer.

@en

P2093

Alexander Sankin

http://www.w3.org/2001/XMLSchema#string

Mark P Schoenberg

http://www.w3.org/2001/XMLSchema#string

Max Kates

http://www.w3.org/2001/XMLSchema#string

Meera R Chappidi

http://www.w3.org/2001/XMLSchema#string

Niv Milbar

http://www.w3.org/2001/XMLSchema#string

Phillip M Pierorazio

http://www.w3.org/2001/XMLSchema#string

Takahiro Yoshida

http://www.w3.org/2001/XMLSchema#string

Trinity J Bivalacqua

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic Studies

Complications after radical cystectomy: analysis of population-based data.

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin

The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.

The health economics of bladder cancer: a comprehensive review of the published literature.

Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy.

Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.

Drug insight: Use of docetaxel in prostate and urothelial cancers.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

P304

293-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/BLC-170126

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Pederzoli

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29152553

http://www.w3.org/2001/XMLSchema#string

P932

5676758

http://www.w3.org/2001/XMLSchema#string

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

about

P2860

P2860

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932